Information Provided By: 
Fly News Breaks for April 8, 2016
MDVN
Apr 8, 2016 | 08:48 EDT
After Europe's drug regulator recommended inclusion of data from the head-to-head trial of Medivation's Xtandi versus bicalutamide in the European label for Xtandi, JMP Securities says that the recommendation leaves Xtandi well-positioned to gain additional market share in Europe. Additionally, the firm thinks that the decision makes Medivation "a more attractive takeover candidate than ever." It reiterates a $56 price target and Outperform rating on Medivation.
News For MDVN From the Last 2 Days
There are no results for your query MDVN
